SAN ANTONIO, Texas, August 7, 2026
bioAffinity Technologies reported second quarter 2026 financial results highlighted by continued commercial momentum for its CyPath® Lung noninvasive lung cancer diagnostic. During the quarter, CyPath Lung test volume increased 216% year over year, reflecting accelerating physician adoption and expanding clinical utilization. Testing revenue for the first six months of 2026 rose 159% to approximately $835,000, while the company delivered 1,097 CyPath Lung reports, compared with 390 during the same period in 2025. The number of physician offices and clinics ordering the test increased 122%, and existing customers boosted orders by 71%, demonstrating growing confidence in the company’s AI-powered lung cancer detection platform.
Commercial Expansion and Clinical Development Continue to Accelerate
bioAffinity continued expanding its commercial footprint while advancing clinical validation of CyPath Lung. The company’s longitudinal clinical trial has begun patient enrollment across 11 clinical sites, including nine Department of Veterans Affairs (VA) and military medical centers, with financial support from the John P. Murtha Cancer Center Research Program. The company also strengthened physician education through scientific presentations, webinars, podcasts, and publication of a comprehensive clinical review outlining the integration of CyPath Lung into pulmonary nodule evaluation and lung cancer surveillance. These initiatives are designed to further increase physician adoption and expand the test’s role in routine clinical practice.
Pipeline Broadens Beyond Lung Cancer Diagnostics
Beyond its flagship diagnostic, bioAffinity Technologies expanded its development pipeline into precision diagnostics for asthma and chronic obstructive pulmonary disease (COPD) as well as topically delivered skin cancer therapeutics. The company presented research supporting biomarker-based diagnostics capable of identifying antibody drug receptors in sputum to better match patients with biologic therapies for asthma and COPD. Additionally, positive preclinical findings demonstrated that its self-delivering stabilized siRNA platform selectively eliminated melanoma, squamous cell carcinoma, and basal cell carcinoma cells while sparing healthy skin tissue. bioAffinity also announced a collaboration with Pictor® to support development of next-generation lung inflammation diagnostics and received a Mexican patent allowance covering key technologies used in its sputum-based lung cancer detection platform.
Advertisement
Financial Results Reflect Continued Commercial Investment
For the second quarter ended June 30, 2026, revenue increased 19% to $1.5 million, driven primarily by higher CyPath Lung sales. Operating expenses rose to $4.8 million, reflecting increased commercialization activities, clinical development, and research investments. Research and development expenses increased 16%, while clinical development expenses rose significantly due to initiation of the longitudinal clinical study. Selling, general, and administrative expenses also increased as the company expanded its commercial organization. Despite these investments, net loss improved to $3.4 million, compared with $4.1 million in the prior-year period. During June, bioAffinity also completed a public offering raising approximately $3.2 million to support commercialization, pipeline development, and general corporate operations as it continues expanding its precision diagnostics portfolio.
Source: bioAffinity Technologies press release
